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Preliminary experience 
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capsules* in cancer patients 
with pain 
Abstract
Background. In an open, clinical study, preliminary assessment of analgesic efficacy and adverse effects of 
prolonged-release morphine sulphate capsules administered once-daily was conducted in patients with 
cancer whose pain required strong opioid analgesics administration.
Material and methods. Seventeen patients participated who were treated with capsules containing 20, 
40 and 60 mg of the drug. The former treatment comprised morphine (8 patients): controlled-release (5), 
immediate-release (one), subcutaneous and the study drug (akin 1 patient), transdermal fentanyl (3), trama-
dol (2), non-opioid analgesics (3) and combination of transdermal buprenorphine with immediate-release 
morphine in one patient. Analgesia was assessed by NRS (Numerical Rating Scale: 0 — no pain, 10 — the 
most severe pain); the result 1–3 was assessed as good, 4–5 as satisfactory, over 5 as unsatisfactory. Adverse 
effects were assessed by verbal scale: 0 — none; 1 — mild; 2 — moderate; 3 — severe.
Results. Treatment lasted 7–161 (mean 50.47 ± 40.51) days; the daily dose range was 20–180 mg. Eleven 
patients (65%) assessed analgesia as good, 5 patients (30%) as partial, one patient (5%) had unsatisfactory 
analgesic effect. Adverse effects observed were as follows: constipation in 9 patients, drowsiness in two 
patients, nausea and vomiting in 2 patients, nausea alone in one patient, dry mouth in one patient.
Conclusions. This preliminary study demonstrated high analgesic efficacy of prolonged-release once-daily 
morphine capsules in the dose range 20–180 mg in cancer patients with pain requiring strong opioid anal-
gesics administration. The treatment was well tolerated with no serious adverse effects observed.
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Introduction
The treatment of pain in cancer is based on phar-
macological approach according to the World Health 
Organisation (WHO) [1] and European Association 
for Palliative Care (EAPC) [2] recommendations with 
the use of analgesics according to three step WHO 
analgesic ladder [3]. Opioid analgesics should be 
administered along with appropriate for each type 
of pain adjuvant analgesics (co-analgesics). In major-
ity of cancer patients with severe pain effective pain 
relief may be achieved thanks to strong opioids (opio-
ids for moderate to severe pain) administered alone 
or in combination with adjuvant analgesics [4]. 
Several non-pharmacological methods may be used 
successfully in cancer patients with pain, namely 
neuromodulation procedures, acupuncture, physi-
cal treatment, the use of blockades and neurolytic 
blocks together with psychosocial and spiritual sup-
port [5].
In Poland controlled-release preparations of 
opioid analgesics are more often being used in 
cancer patients with pain. In spite of other strong 
opioids available in Poland (fentanyl, buprenorphine, 
oxycodone, methadone) morphine is still the most 
popular and an effective opioid for moderate to se-
vere pain [6]. In a long-term therapy of chronic pain 
immediate-release morphine formulations (water 
solution and tablets) are most frequently substituted 
with regular administration of controlled-release 
morphine administered usually twice daily; the 
short-acting formulations are used for breakthrough 
pain management. A further progress in chronic 
pain management is the introduction of morphine 
sulphate controlled-release capsules (20, 40, 60, 120 
and 200 mg strength) designed for once a day admi-
nistration. The aim of the study was the preliminary 
assessment of analgesia and adverse effects during 
administration of morphine sulphate controlled-re-
lease capsules (20, 40, and 60 mg strength) designed 
for once a day administration in cancer patients with 
pain requiring opioid for moderate to severe pain 
treatment.
Material and methods
An open clinical study conducted after regis-
tration of the study drug (Oramorph O.D.®, Mol-
teni) in Poland. All patients had advanced cancer. 
Patients with renal impairment (serum creatinine 
level over 1.3 mg%) and with symptoms of delirium 
were excluded from the participation in the study. 
All patients were recruited from those treated at 
the Day Palliative Care Centre and those staying at 
home cared by a home palliative care team (Home 
Hospice) both attached to the Chair and Department 
of Palliative Medicine at Poznan University of Medical 
Sciences. The study drug was administered in three 
capsule strengths: 20, 40 and 60 mg, in daily dos-
es up to 180 mg. Apart from regular administration 
of the study drug all patients were prescribed imme-
diate-release oral morphine formulations (tablets or 
water solution) for breakthrough pain management 
at single doses 5–20 mg depending on the regular 
dose of morphine. The study medication was ad-
ministered to 17 patients with cancer whose pain 
required strong opioid analgesics administration. 
The decision of the commence of therapy was made 
individually by a physician, after obtaining consent 
from patients. 
Patients recruited for the study were formerly 
treated with strong opioids (12 patients), as well 
as five patients who were formerly treated with weak 
opioids, namely tramadol (two patients) or non-opi-
oid analgesics (3 patients). In the first group 8 pa-
tients were previously treated with morphine: 5 pa-
tients received controlled-release preparations twice 
daily, one patient received immediate-release formu-
lation every 4 h, one patient received morphine sub-
cutaneously, and one patient was already receiving 
the study drug. All these patients while on former 
morphine formulations had effective analgesia, 
thus the same equivalent once daily morphine dose 
was prescribed (20–60 mg). Three patients were 
formerly treated with transdermal fentanyl (TF) and 
one with transdermal buprenorphine (TB) in a com-
bination with immediate-release morphine adminis-
tered every 4 h; in all these cases the treatment did 
not provide satisfactory analgesia. In one patient 
a dose of TF 37.5 μg/h was substituted with the 
study drug at a dose of 40 mg. In one patient the TF 
dose was 25 μg/h and the study drug was added at 
a dose of 20 mg. In another patient the TF 50 μg/h 
patch was substituted with the study drug at a dose 
of 60 mg. A patient who received TB at a dose 52.5 
μg/h with immediate-release morphine 5 mg every 
4 h the latter was substituted with the study drug 
at a dose of 60 mg while continuing TB treatment. 
In all patients who were formerly treated unsuccess-
fully with tramadol (at a dose of 200 mg daily with 
poor tolerance and 400 mg daily without satisfac-
tory analgesia) or with non-opioid analgesics alone 
the study drug was started at a dose of 20 mg daily.
The patients had the following primary tumours: 
lung (6 patients), breast (3 patients), rectum (2 pa-
tients), prostate, palatine tonsil, mediastinum, uri-
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nary bladder, pancreas, unknown primary tumour 
with bone metastases akin 1 patient. Most pa-
tients suffered from somatic bone pain (9 patients) 
somatic from soft tissues (2 patients), visceral pain 
(6 patients), neuropathic (5 patients) and pain due 
to raised intracranial pressure (1 patient). Eleven 
patients suffered from one type of pain; in 6 pa-
tients mixed pain syndromes were observed: bone 
and neuropathic (3 patients), bone and visceral, neu-
ropathic and somatic from soft tissues, neuropathic 
and visceral akin 1 patient. Patients continued the 
former treatment with co-analgesics: antidepres-
sants and anticonvulsants in neuropathic pain and 
non-steroid anti-inflammatory drugs and bisphos-
phonates in bone pain. In all patients who were 
opioid-naive or stopped tramadol metoclopramide 
10 mg three times daily and lactulose twice daily 
15 ml were administered. Analgesia was assessed 
twice a week by NRS (Numerical Rating Scale: 0 
— no pain; 10 — the most severe pain). The score 
1–3 was evaluated as good, 4–5 as satisfactory, 
over 5 as unsatisfactory. Pain intensity and adverse 
effects was assessed at baseline and every two 
days during the treatment. Adverse effects were 
assessed by a verbal scale: 0 — none; 1 — mild; 
2 — moderate; 3 — severe. The study protocol 
was approved by the Regional Ethics Committee at 
the Poznan University of Medical Sciences.
Results
The age of patients was 53–85 (the mean 
68.53 ± 8.67), there were twelve men and 5 women. 
The time of the treatment was 7–161 (the mean 
50.47 ± 40.51) days, the dose range 20–180 mg: 
the mean starting dose was 42.35 ± 19.26 mg and 
the mean final dose was 61.18 ± 42.55 mg. Eleven 
patients (65%) assessed analgesia as good, 5 pa-
tients (30%) as satisfactory, one patient (5%) had 
unsatisfactory analgesic effect. This patient with 
bone and neuropathic pain due to bone metas-
tases from prostate cancer stopped the treatment 
due to ineffective analgesia after 7 days and returned 
to his former schedule with controlled-release mor-
phine administered twice daily with good analgesia. 
Patients who had satisfactory analgesia were those 
two with bone metastases from unknown primary 
tumour and from lung cancer, one patient with lung 
cancer and oesophagus infiltration, one patient 
with lung cancer and local pain and a patient with 
somatic and neuropathic pain due to palatine tonsil 
cancer. The respective daily doses of the study drug 
were as follows: 20–120 mg, 20 mg, 60 mg, 60 mg, 
and 60–180 mg. Patients who experienced good 
analgesia were treated with the daily dose range of 
the study drug 20 mg (four patients), 40 mg (one 
patient), 60 mg (three patients), 20–40 mg (one 
patient), 60–80 mg (one patient), and 60–120 mg 
(one patient); two of those patients were treated 
concurrently with TF (25 μg/h) and TB (52.5 μg/h); 
the study drug daily doses were 20 mg and 60 mg, 
respectively.
The treatment with the study drug was con-
tinued until the end of life in three patients. In 4 
patients morphine was administered subcutaneously 
due to general deterioration before death and in-
ability to take medications orally. In another three 
patients therapy with the study drug was continued 
at the time of study evaluation; in 5 patients the 
treatment was stopped due to unavailability of the 
study drug and all these patients were switched 
to the treatment with controlled-release morphine 
administered twice daily. One patient was lost to 
follow up due to a stay in another hospital until her 
death. As mentioned above one patient stopped the 
treatment due to lack of efficacy of the study drug.
Adverse effects observed were as follows: consti-
pation in 9 patients (in two severe demanding several 
enemas, in 5 moderate, in 2 mild), drowsiness in 2 
patients (in one patient of mild and in another of 
moderate intensity), nausea and vomiting in two 
patients (moderate and mild akin 1), nausea alone 
in one patient, dry mouth also in one patient. In one 
patient choreatic movement exacerbated but the 
symptom was attributed to the Parkinson disease. No 
severe adverse effects were observed such as respira-
tory depression or allergy for the drug.
Discussion
The results of the study indicate high analgesic ef-
ficacy of the new prolonged-release morphine formu-
lation in the treatment of cancer patients with pain 
requiring strong opioids administration. In 11 from 
seventeen patients recruited analgesia was good, 
which concerned both patients treated formerly with 
morphine, fentanyl and two patients who required 
strong opioids administration due to ineffective anal-
gesia and poorly tolerated tramadol treatment. Good 
analgesia was also observed in two patients who 
received concurrently TF and TB. Positive effects were 
achieved in patients with both receptor and neuro-
pathic types of pain. Unsatisfactory analgesia was ob-
served in one patient diagnosed with prostate cancer 
and bone metastases. In this patient the study drug 
was used at a dose of 60 mg per day; however, the 
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analgesic effect was unsatisfactory in the morning 
hours before the next dose administration. The pa-
tient returned to his former treatment schedule (one 
controlled-release morphine tablet at a dose 30 mg, 
every 12 h) and achieved satisfactory pain relief for 
24 h; after several weeks of the treatment the dose 
was increased to 40 and then to 60 mg twice daily 
due to disease progression and more intense pain. 
Perhaps the cause of the treatment failure was ac-
celerated gastrointestinal motility although special 
tests were not conducted. Five patients assessed 
analgesia as satisfactory; most of these patients suf-
fered from bone or neuropathic pain and needed 
higher morphine doses although an uncontrolled 
study design and a small study sample does not al-
low drawing equivocal conclusions.
It should be emphasized that the tolerance of the 
treatment was generally good. Constipation was ob-
served in 9 patients (in two severe demanding several 
enemas, in 5 moderate, in 2 mild), drowsiness in 2 
patients (in one patient of mild and in another of 
moderate intensity), nausea and vomiting in two 
patients (moderate and mild akin 1), nausea alone 
in one patient, dry mouth also in one patient. All pa-
tients with constipation demanded laxatives adminis-
tration (lactulose, senna and glycerine suppositories), 
which in most cases caused bowel movement every 
other day. However, in two patients constipation 
was severe and required enemas. Drowsiness was ob-
served at the beginning of the treatment in one pa-
tient and disappeared without treatment; in another 
patient drowsiness was probably due to progressive 
cachexia that led to a patient’s death. Nausea and 
vomiting was observed in a patient with brain me-
tastases, which could have been the cause of the 
symptoms but also due to morphine administration. 
The symptoms were also apparent in a patient with 
advanced lung cancer and severe cachexia despite an-
tiemetic administration. No severe adverse effects ap-
peared especially respiratory depression or allergy to 
the drug. The low incidence and mild to moderate in-
tensity of adverse effects was probably due to the fact 
that most patients were formerly treated with strong 
opioids including 8 patients treated with morphine at 
the same doses as the study drug and the prophylactic 
use of metoclopramide in opioid-naive patients and 
those who started the study drug after tramadol. 
Another factor could be that all patients recruited 
had normal renal function as in case of renal impair-
ment morphine adverse effects are more frequent 
and more intense [7].
Our results are comparable to the experience of 
other authors who used controlled-release morphine 
sulphate tablets and capsules administered twice 
daily that were effective in most cancer patients with 
pain requiring strong opioid administration [8]. The 
convenience of the new morphine capsules formu-
lation that demand once daily administration every 
24 h should be emphasized. Similarly as in the case 
of morphine controlled-release capsules designed 
for twice daily administration [9] the advantage of 
the new morphine capsule formulation designed for 
once daily administration is the possibility of opening 
the capsule and administration of the content (mi-
crocapsules) with pap-like food without disturbing 
the controlled-release system of drug. This was con-
firmed in our large, multicenter study conducted in 
patients with cancer and chronic, non-malignant 
pain [10]. It is important for patients with dysphagia 
and for those fed by nasogastric tube and gastros-
tomy with 16 FG or bigger diameter. It is also an ad-
vantage of the study drug in comparison to morphine 
tablets administered once-daily [11, 12]. According 
to the manufacturer drug recommendations mor-
phine sulphate prolonged-release capsules designed 
for once-daily administration may be given to pa-
tients formerly treated with immediate-release or 
controlled-release morphine administered every 
4–6 h or every 12 h, respectively [13]. In the light of 
our observation it seems feasible to administer the 
study drug in patients who were formerly treated 
with TF at doses 37.5 and 50 μg/h. It was also pos-
sible to concurrently treat patients with TF 25 μg/h or 
TB 52.5 μg/h with the study drug at daily doses 20 mg 
and 60 mg (in this case instead of regularly admin-
istered immediate-release morphine), respectively 
[14, 15] with good analgesic effects. The treatment 
was also successful in patients treated formerly with 
weak opioids namely tramadol who did not achieve 
satisfactory analgesia at a full dose (400 mg). It 
was also possible to administer successfully the 
study drug in opioid-naive patients who suffer from 
severe pain demanding opioids for moderate to 
severe pain administration. In all these cases the 
starting dose was 20 mg once daily, although these 
approaches need more data. Due to a possible nega-
tive interaction of the concurrent study drug admi-
nistration and alcohol intake (dr Arleta Kaczmarek, dr 
Wojciech Stanek, Molteni Poland, personal commu-
nication) and unavailability of the study medication 
the treatment was completed in five patients who 
were switched to the controlled-release morphine 
administered twice daily. However, in vitro studies did 
not demonstrate increased release of morphine from 
prolonged-release tablets in the presence of ethanol 
4–40% [16]. 
www.advpm.eu 27
Wojciech Leppert et al., Once-daily prolonged-release morphine in cancer pain
Several limitations of the study should be ad-
dressed. It was a pilot survey with a small study sam-
ple recruited; moreover, it was a heterogenic group 
of patients with different primary tumours, different 
types of pain and different pain medications admin-
istered before entering the study. However, due to 
these features it was more alike to everyday clinical 
practice situation rather the clinical trial. Due to these 
limitations the results achieved need verification in 
a larger patient group with a controlled study design. 
Further limitations include an open design without 
comparators and lack of a control group. Most pa-
tients recruited were those treated formerly with other 
morphine formulations that provided satisfactory 
analgesia. The observation was limited to analgesia 
and adverse effects reported by patients without 
the use of more precise tools such as pain, adverse 
effects and quality of life questionnaires. The time 
of the treatment was quite different in individual 
patients. The study was conducted in one centre and 
all patients were treated at out-patient palliative care 
clinic, day care centre or at home. In spite of nume-
rous limitations preliminary results indicate on the 
usefulness of morphine sulphate prolonged-release 
capsules (20, 40, and 60 mg strength) designed for 
once-daily administration in cancer patients with pain 
requiring opioids for moderate to severe pain treat-
ment. Both satisfactory analgesia as well as beneficial 
profile of adverse effects encourages further compara-
tive studies with other strong opioids taking into con-
sideration analgesia, adverse effects, pharmacokinetic 
profiles of drugs studied and patients’ quality of life.
In conclusions the use of morphine sulphate pro-
longed-release capsules (20, 40, and 60 mg strength) 
administered once-daily in cancer patients with pain 
requiring treatment with opioid for moderate to se-
vere pain in the daily dose range 20–180 mg provided 
in all but one patient good or satisfactory analgesia. 
It refers to strong-opioid tolerant patients as well 
as those treated formerly unsuccessfully with weak 
opioids (tramadol) and opioid-naive patients. The 
tolerance of the treatment was good; the observed 
adverse effects were constipation, drowsiness, nau-
sea and vomiting in most cases of mild to moderate 
intensity with no serious adverse effects.
*The production of the medicine has been halted 
and it is no longer available (Ed.).
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